Skip to main content

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Aproximaciones al manejo de la enfermedad avanzanda en cáncer de endometrio a través de la identificación de biomarcadores en biopsia líquida

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Nuria Laia Rodriguez Mias
Funding agency: Instituto de Salud Carlos III
Funding: 100430
Reference: PI17/02071
Duration: 01/01/2018 - 31/12/2021

Desarrollo de una herramienta molecular para el diagnóstico y pronóstico en cáncer de endometrio

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Eva Colas Ortega, Silvia Cabrera Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 85250
Reference: DTS17/00146
Duration: 01/01/2018 - 31/12/2020

Anatomia Patològica (GRC)

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Cleofé Romagosa Pérez-Portabell, Inés de Torres Ramirez, Angel García Jiménez, Josep Castellví Vives, Maria Teresa Salcedo Allende, Javier Hernandez Losa, Marta Sese Faustino, Vicente Peg Camara, Irene Sansano Valero, Stefania Landolfi , Trond Aasen
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 1131
Duration: 01/01/2014 - 31/12/2016

Desarrollo de Marcadores y Terapias en Cáncer de Endometrio Avanzado

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Maria Asuncion Perez Benavente, Fco Javier De la Torre Fdez de Vega, Josep Castellví Vives, Silvia Cabrera Diaz, Marina Rigau Resina
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI14/02043
Duration: 01/01/2015 - 30/06/2019

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

M. Mercè Fabregat  Bosch

M. Mercè Fabregat Bosch

Reconstructive Surgery of the Locomotor System
Read more
José Alonso Fajardo

José Alonso Fajardo

Shock, Organ Dysfunction and Resuscitation
Read more
Eulàlia Pérez Esquirol

Eulàlia Pérez Esquirol

Senior researcher
Clinical Pharmacology
Read more
José Antonio Navarro Sanchís

José Antonio Navarro Sanchís

Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.